B002 in Patients With HER2-positive Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Recurrent Breast Cancer|Metastatic Breast Cancer
Interventions: BIOLOGICAL: Humanized Anti-HER2 Monoclonal Antibody Compound for Injection .R&D code: B002.
Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd